Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall

Phyu P. Aung; Naveen Pemmaraju; Carlos A. Torres-Cabala; Madeleine Duvic; Marina Konopleva; Joseph D. Khoury; Victor G. Prieto

doi:10.1111/1346-8138.15456

Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall

Phyu P. Aung, Naveen Pemmaraju, Carlos A. Torres-Cabala, Madeleine Duvic, Marina Konopleva, Joseph D. Khoury, Victor G. Prieto

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	e354-e355
Journal	Journal of Dermatology
Volume	47
Issue number	10
DOIs	https://doi.org/10.1111/1346-8138.15456
State	Published - Oct 1 2020
Externally published	Yes

ASJC Scopus subject areas

Dermatology

Access to Document

10.1111/1346-8138.15456

Cite this

Aung, P. P., Pemmaraju, N., Torres-Cabala, C. A., Duvic, M., Konopleva, M., Khoury, J. D., & Prieto, V. G. (2020). Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. Journal of Dermatology, 47(10), e354-e355. https://doi.org/10.1111/1346-8138.15456

Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. / Aung, Phyu P.; Pemmaraju, Naveen; Torres-Cabala, Carlos A. et al.
In: Journal of Dermatology, Vol. 47, No. 10, 01.10.2020, p. e354-e355.

Research output: Contribution to journal › Letter › peer-review

Aung, PP, Pemmaraju, N, Torres-Cabala, CA, Duvic, M, Konopleva, M, Khoury, JD & Prieto, VG 2020, 'Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall', Journal of Dermatology, vol. 47, no. 10, pp. e354-e355. https://doi.org/10.1111/1346-8138.15456

@article{ad7f5772dcb74bb0bfa621b0efd92919,

title = "Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall",

author = "Aung, {Phyu P.} and Naveen Pemmaraju and Torres-Cabala, {Carlos A.} and Madeleine Duvic and Marina Konopleva and Khoury, {Joseph D.} and Prieto, {Victor G.}",

note = "Funding Information: N. P. reports consulting fees and honoraria from AbbVie, Celgene, Stemline, Incyte, Novartis, MustangBio and Roche Diagnostics, LFB; research funding/clinical trials support from Stemline, Novartis, AbbVie, Samus, Cellectis, Plexxikon, Daiichi‐Sankyo, and Affymetrix; and grants/funding from Affymetrix and SagerStrong Foundation. M. K. reports consulting fees/honoraria and research funding/clinical trials support from Stemline Therapeutics. The other authors report no conflicts of interest. Funding Information: The authors thank Ms Stephanie Deming, ELS, Senior Scientific Editor, Scientific Publication Services, Research Medical Library, The University of Texas MD Anderson Cancer Center, for assistance with editing of this manuscript.",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/1346-8138.15456",

language = "English (US)",

volume = "47",

pages = "e354--e355",

journal = "Journal of Dermatology",

issn = "0385-2407",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy

T2 - A novel finding and possible diagnostic pitfall

AU - Aung, Phyu P.

AU - Pemmaraju, Naveen

AU - Torres-Cabala, Carlos A.

AU - Duvic, Madeleine

AU - Konopleva, Marina

AU - Khoury, Joseph D.

AU - Prieto, Victor G.

N1 - Funding Information: N. P. reports consulting fees and honoraria from AbbVie, Celgene, Stemline, Incyte, Novartis, MustangBio and Roche Diagnostics, LFB; research funding/clinical trials support from Stemline, Novartis, AbbVie, Samus, Cellectis, Plexxikon, Daiichi‐Sankyo, and Affymetrix; and grants/funding from Affymetrix and SagerStrong Foundation. M. K. reports consulting fees/honoraria and research funding/clinical trials support from Stemline Therapeutics. The other authors report no conflicts of interest. Funding Information: The authors thank Ms Stephanie Deming, ELS, Senior Scientific Editor, Scientific Publication Services, Research Medical Library, The University of Texas MD Anderson Cancer Center, for assistance with editing of this manuscript.

PY - 2020/10/1

Y1 - 2020/10/1

UR - http://www.scopus.com/inward/record.url?scp=85089103927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089103927&partnerID=8YFLogxK

U2 - 10.1111/1346-8138.15456

DO - 10.1111/1346-8138.15456

M3 - Letter

C2 - 32770556

AN - SCOPUS:85089103927

SN - 0385-2407

VL - 47

SP - e354-e355

JO - Journal of Dermatology

JF - Journal of Dermatology

IS - 10

ER -

Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this